140 related articles for article (PubMed ID: 29767871)
1. Expression and clinical significance of Ki-67, E-cadherin, and mesothelin in serous borderline ovarian tumor.
Yu N; Wang N; Liu YF; Li YY; Zhang TG
Eur J Gynaecol Oncol; 2017; 38(1):85-90. PubMed ID: 29767871
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
[TBL] [Abstract][Full Text] [Related]
4. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
[TBL] [Abstract][Full Text] [Related]
5. [Expression of mesothelin mRNA and protein in ovarian carcinomas].
Bi SN; Dai SZ; Yao Q; Che YC; Wang N
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):288-91. PubMed ID: 18788634
[TBL] [Abstract][Full Text] [Related]
6. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases.
Daraï E; Scoazec JY; Walker-Combrouze F; Mlika-Cabanne N; Feldmann G; Madelenat P; Potet F
Hum Pathol; 1997 Aug; 28(8):922-8. PubMed ID: 9269828
[TBL] [Abstract][Full Text] [Related]
7. Immunoexpression of beta-catenin--E-cadherin complex in primary serous ovarian tumors.
Stawerski P; Wagrowska-Danilewicz M; Stasikowska O; Gottwald L; Danilewicz M
Pol J Pathol; 2008; 59(1):27-32. PubMed ID: 18655368
[TBL] [Abstract][Full Text] [Related]
8. The Epithelial-Mesenchymal Transition, E-cadherin and Tumor Progression in Ovarian Serous Tumors.
Bozhkova DM; Poryazova-Markova EG
Folia Med (Plovdiv); 2019 Jun; 61(2):296-302. PubMed ID: 31301662
[TBL] [Abstract][Full Text] [Related]
9. A rat model of serous borderline ovarian tumors induced by 7,12-dimethylbenz[a]anthracene.
Cai SQ; Li Y; Li YA; Wang L; Zhu J; Zhao SH; Li X; Qiang JW
Exp Anim; 2019 Aug; 68(3):257-265. PubMed ID: 30760660
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.
Hanaoka T; Hasegawa K; Kato T; Sato S; Kurosaki A; Miyara A; Nagao S; Seki H; Yasuda M; Fujiwara K
Mol Diagn Ther; 2017 Apr; 21(2):187-198. PubMed ID: 28160193
[TBL] [Abstract][Full Text] [Related]
12. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.
De Nictolis M; Garbisa S; Lucarini G; Goteri G; Masiero L; Ciavattini A; Garzetti GG; Stetler-Stevenson WG; Fabris G; Biagini G; Prat J
Int J Gynecol Pathol; 1996 Apr; 15(2):102-9. PubMed ID: 8786198
[TBL] [Abstract][Full Text] [Related]
13. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
14. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
15. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas.
Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Ferreira VM; Lopes CS
Hum Pathol; 2004 Jun; 35(6):663-9. PubMed ID: 15188131
[TBL] [Abstract][Full Text] [Related]
16. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
18. The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles.
Zeller C; Dai W; Curry E; Siddiq A; Walley A; Masrour N; Kitsou-Mylona I; Anderson G; Ghaem-Maghami S; Brown R; El-Bahrawy M
Am J Pathol; 2013 Mar; 182(3):668-77. PubMed ID: 23357500
[TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass.
Yu XP; Liu Y; Jiao JW; Yang HJ; Wang RJ; Zhang S
Med Sci Monit; 2020 Aug; 26():e924497. PubMed ID: 32801292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
